Development of SLIC, a methodology for synthetic lethal screening in the CNS
Development of SLIC, a methodology for synthetic lethal screening in the CNS
批准号:
8889737
负责人:
Myriam Heiman
金额:
$35.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-25 至 2016-06-30
关键词:
Affinity ChromatographyAgeAnimal ModelAnimalsBar CodesBrainCaenorhabditis elegansCell DeathCell physiologyCellsCellular biologyCorpus striatum structureDNA SequenceDependencyDevelopmentDiseaseDisease modelDropsEnhancersEnvironmentEtiologyGenerationsGenesGenetic ScreeningGenomeGoalsHealthHumanHuntington DiseaseIn VitroIndividualInjection of therapeutic agentInstitutesLeadLentivirus VectorLibrariesMethodologyModelingMolecularMolecular ProfilingMusMutationNatureNeuraxisNeurodegenerative DisordersNeuronsNeurosciences ResearchOperative Surgical ProceduresPathway interactionsPatientsPredispositionRNA InterferenceResearchResearch PersonnelRibosomesSaccharomyces cerevisiaeSequence AnalysisSubfamily lentivirinaeTherapeuticToxic effectTranslatingVertebratesViralWild Type MouseWorkcell typecostgene discoverygenetic manipulationgenome-widegenome-wide analysishuman Huntingtin proteinin vivomeetingsmouse modelmutantnext generation sequencingnoveloverexpressionscreeningsmall hairpin RNAsuccesstherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Challenge: New hypotheses in the neurodegenerative disease research field are needed, given the lack of effective therapeutics for most of the major diseases. In simple model organisms, unbiased, genome-wide genetic screens are used to generate new hypotheses in an unbiased way. Synthetic lethal genetic screens are genetic screens in which a mutation that has no or little toxicity is enhanced by an additional genetic manipulation into a mutation that now does. Thus 'synthetic lethal' screens are used to reveal genes and pathways that genetically interact with toxic mutations. Currently it is not feasible to conduct such genetic screens in mice, due to prohibitive cost and numbers of animals needed. We propose to develop a strategy for synthetic lethal in the central nervous system (CNS), which we term SLIC. Impact: The ability to perform unbiased, genome-wide screens in the mouse CNS with our SLIC methodology would allow for the generation of novel hypotheses regarding the etiology of neurodegenerative disease. The potential impact would be myriad new avenues to explore potential therapeutic targets. Once developed, our SLIC methodology could be applied by other researchers to the study of any genetically-induced disease. Approach: We view the lack of cell death found in most mouse models of neurodegenerative disease as a unique opportunity. We propose to conduct synthetic lethal screens in mouse brain, to enhance the toxicity of neurodegenerative disease-associated mutations. SLIC synthetic lethal screens will be conducted by combining the use of i) lentirival shRNA or inducible, barcoded overexpression libraries; ii) stereotaxic CNS injection of these libraries into mouse models of disease and wild-type littermates; iii) incubation of injected libraries, such that shRNAs or overexpressed genes that enhance toxicity will lead to cell death; iv) sequencing and analysis of the remaining shRNAs and barcoded overexpression constructs in all surviving cells, in order to determine which constructs have led to cell death, and thus 'drop out' of viral representation. Our work will be conducted along the following specific aims: Aim 1. To develop a methodology that allows for synthetic lethal screens in the mouse central nervous system (CNS); Aim 2. To identify, using the methodology developed in Aim 1, enhancers of Huntingtin toxicity in vivo
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Mechanisms Underlying Cell Type-Specific Vulnerability in Huntington’s Disease
-
批准号:10457670
-
项目类别:
-
资助金额:$54.29万
-
财政年份:2022
-
负责人:Myriam Heiman
-
依托单位:
Molecular Mechanisms Underlying Cell Type-Specific Vulnerability in Huntington’s Disease
-
批准号:10614595
-
项目类别:
-
资助金额:$54.29万
-
财政年份:2022
-
负责人:Myriam Heiman
-
依托单位:
Single-cell multi-region transcriptional and epigenomic dissection of VCID.
-
批准号:10532050
-
项目类别:
-
资助金额:$305.85万
-
财政年份:2022
-
负责人:Myriam Heiman
-
依托单位:
Reverse engineering zonation-specific and age-specific iPSC-derived cerebrovascular models based on transcriptomic profiling of the human brain
-
批准号:10321473
-
项目类别:
-
资助金额:$83.31万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV
-
批准号:10672447
-
项目类别:
-
资助金额:$243.39万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Determinants of cell type-specific vulnerability in Huntington's disease
-
批准号:10440179
-
项目类别:
-
资助金额:$36.5万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV
-
批准号:10478928
-
项目类别:
-
资助金额:$244.79万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Reverse engineering zonation-specific and age-specific iPSC-derived cerebrovascular models based on transcriptomic profiling of the human brain
-
批准号:10916740
-
项目类别:
-
资助金额:$45.78万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV
-
批准号:10220620
-
项目类别:
-
资助金额:$246.19万
-
财政年份:2021
-
负责人:Myriam Heiman
-
依托单位:
Determinants of cell type-specific vulnerability in Huntington's disease
-
批准号:9418649
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2017
-
负责人:Myriam Heiman
-
依托单位:
Determinants of cell type-specific vulnerability in Huntington's disease
-
批准号:9285159
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2017
-
负责人:Myriam Heiman
-
依托单位:
Determinants of cell type-specific vulnerability in Huntington's disease
-
批准号:9910469
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2017
-
负责人:Myriam Heiman
-
依托单位:
Development of SLIC, a methodology for synthetic lethal screening in the CNS
-
批准号:9097820
-
项目类别:
-
资助金额:$35.4万
-
财政年份:2013
-
负责人:Myriam Heiman
-
依托单位:
Development of SLIC, a methodology for synthetic lethal screening in the CNS
-
批准号:8639854
-
项目类别:
-
资助金额:$34.6万
-
财政年份:2013
-
负责人:Myriam Heiman
-
依托单位:
Development of SLIC, a methodology for synthetic lethal screening in the CNS
-
批准号:8742024
-
项目类别:
-
资助金额:$35.05万
-
财政年份:2013
-
负责人:Myriam Heiman
-
依托单位:
Animal Core
-
批准号:8150139
-
项目类别:
-
资助金额:$41.42万
-
财政年份:2010
-
负责人:Myriam Heiman
-
依托单位:
Cell Specific Analysis of Psychostimulant Drug Action
-
批准号:7254079
-
项目类别:
-
资助金额:$5.2万
-
财政年份:2006
-
负责人:Myriam Heiman
-
依托单位:
Cell Specific Analysis of Psychostimulant Drug Action
-
批准号:7113453
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2006
-
负责人:Myriam Heiman
-
依托单位:
Animal Core
-
批准号:8328721
-
项目类别:
-
资助金额:$45.19万
-
财政年份:--
-
负责人:Myriam Heiman
-
依托单位:
Animal Core
-
批准号:8382719
-
项目类别:
-
资助金额:$32.9万
-
财政年份:--
-
负责人:Myriam Heiman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: